Virtanen, V.; Paunu, K.; Ahlskog, J.K.; Varnai, R.; Sipeky, C.; Sundvall, M.
PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development. Genes 2019, 10, 565.
https://doi.org/10.3390/genes10080565
AMA Style
Virtanen V, Paunu K, Ahlskog JK, Varnai R, Sipeky C, Sundvall M.
PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development. Genes. 2019; 10(8):565.
https://doi.org/10.3390/genes10080565
Chicago/Turabian Style
Virtanen, Verneri, Kreetta Paunu, Johanna K. Ahlskog, Reka Varnai, Csilla Sipeky, and Maria Sundvall.
2019. "PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development" Genes 10, no. 8: 565.
https://doi.org/10.3390/genes10080565
APA Style
Virtanen, V., Paunu, K., Ahlskog, J. K., Varnai, R., Sipeky, C., & Sundvall, M.
(2019). PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development. Genes, 10(8), 565.
https://doi.org/10.3390/genes10080565